Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin



      In this article, we report the outcomes of patients with deep venous thrombosis in the lower limbs treated with the oral anticoagulant rivaroxaban or warfarin, focusing on the recanalization rate (measured with duplex ultrasound) and the incidence of postthrombotic syndrome.


      This was a prospective, consecutive, randomized, blind cohort study of patients admitted with deep venous thrombosis to the Division of Vascular and Endovascular Surgery, Hospital do Servidor Público Estadual, São Paulo, Brazil, between March 2016 and July 2018. The patients were randomized into 2 groups and treated with oral anticoagulation for 6 months: either rivaroxaban (group 1) or warfarin (group 2). The study was registered at under NCT 02704598.


      Eighty-eight patients with deep venous thrombosis were admitted to the Vascular Surgery Department and randomized into the 2 groups. The follow-up time was 360 days. Analyses were performed at 180 and 360 days. Four patients were excluded from the study during follow-up because of a diagnosis of ovarian cancer (1 patient), head and neck cancer (1 patient), lung cancer (1 patient), and stomach cancer (1 patient). Therefore, 84 patients were evaluated: 46 patients in group 1 and 38 in group 2. The incidence of postthrombotic syndrome was 17.9% (15 cases) in the total cohort, but was significantly higher in group 2 (11 cases, 28.9%) than in group 1 (4 cases, 8.7%; P < .001; odds ratio, 4.278). The rate of total venous recanalization at 360 days was 40.5% (34 patients) in the total cohort, but was significantly higher in group 1 (35 patients, 76.1%) than in group 2 (5 patients, 13.2%; P < .001). The incidence of partial venous recanalization was 46.4% and was significantly higher in group 2 (28 patients, 73.7%) than in group 1 (11 patients, 23.9%; P = .016). Five patients in the total cohort (6%) showed no venous recanalization, all of them in group 2 (P = .016).


      In this study, patients who received oral rivaroxaban displayed a lower incidence of postthrombotic syndrome and a better total vein recanalization rate after 6 and 12 months than patients who received warfarin.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kearon C.
        • Akl E.A.
        • Comerota A.J.
        • et al.
        Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012 Feb; 141: e419S-e496S
        • Caprini J.A.
        Risk assessment as a guide for the prevention of the many faces of venous thromboembolism.
        Am J Surg. 2010; 14: 139-144
        • Kniffin Jr., W.D.
        • Baron J.A.
        • Barrett J.
        • Birkmeyer J.D.
        • Anderson Jr., F.A.
        The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly.
        Arch Intern Med. 1994; 154: 861-866
        • Kahn S.R.
        • Comerota A.J.
        • Cushman M.
        • et al.
        American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The post-thrombotic syndrome: Evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association.
        Circulation. 2014; 130: 1636-1661
        • Guanella R.
        • Ducruet T.
        • Johri M.
        • et al.
        Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: A prospective evaluation.
        J Thromb Haemost. 2011; 9: 2397-2456
        • Villalta S.
        • Bagatella P.
        • Piccioli A.
        • Lensing A.W.A.
        • Prins M.H.
        • Prandoni P.
        Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome.
        Haemostasis. 1994; 24: 158a
        • van Dongen C.J.
        • Prandoni P.
        • Frulla M.
        • Marchiori A.
        • Prins M.H.
        • Hutten B.A.
        Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome.
        J Thromb Haemost. 2005; 3: 939-942
        • Prandoni P.
        • Frulla M.
        • Sartor D.
        • Concolato A.
        • Girolami A.
        Vein abnormalities and the post-thrombotic syndrome.
        J Thromb Haemost. 2005; 3: 401-402
        • Baglin T.
        Prevention of post-thrombotic syndrome: A case for new oral anticoagulant drugs or for heparins?.
        J Thromb Haemost. 2012; 10: 1702-1703
        • Bauersachs R.
        • Berkowitz S.D.
        • Brenner B.
        • et al.
        Oral rivaroxaban for symptomatic venous thromboembolism.
        N Engl J Med. 2010; 363: 2499-2510
        • Buller H.R.
        • Prins M.H.
        • Lensin A.W.
        • et al.
        • EINSTEIN–PE Investigators
        Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
        N Engl J Med. 2012; 366: 1287-1297
        • Cheung Y.W.
        • Middeldorp S.
        • Prins M.H.
        • et al.
        • EINSTEIN PTS Investigators Group
        Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis.
        Thromb Haemost. 2016; 116: 733-738
        • Michiels J.J.
        • Moosdorff W.
        • Maasland H.
        • et al.
        Duplex ultrasound, clinical score, thrombotic risk, and D-dimer testing for evidence based diagnosis and management of deep vein thrombosis and alternative diagnoses in the primary care setting and outpatient ward.
        Int Angiol. 2014; 33: 1-19
        • Coleman C.I.
        • Beyer-Westendorf J.
        • Bunz T.J.
        • Mahan C.E.
        • Spyropoulos A.C.
        Postthrombotic syndrome in patients treated with rivaroxaban or warfarin for venous thromboembolism.
        Clin Appl Thromb Hemost. 2018; 24: 575-582
        • Partsch H.
        Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation.
        Vasa. 2001; 30: 195-204
        • Prandoni P.
        • Kahn S.R.
        Post-thrombotic syndrome: Prevalence, prognostication and need for progress.
        Br J Haematol. 2009; 145: 286-295
        • Ouriel K.
        • Green R.M.
        • Greenberg R.K.
        • Clair D.G.
        The anatomy of deep venous thrombosis of the lower extremity.
        J Vasc Surg. 2000; 31: 895-900
        • Cowell G.W.
        • Reid J.H.
        • Simpson A.J.
        • Murchison J.T.
        A profile of lower-limb deep vein thrombosis: The hidden menace of below-knee DVT.
        Clin Radiol. 2007; 62: 858-863
        • May R.
        • Thurner J.
        The cause of predominantly sinistral occurrence of thrombosis of the pelvic veins.
        Angiology. 1957; 8: 419-427
        • Dronkers C.E.A.
        • Mol G.C.
        • Maraziti G.
        • et al.
        Predicting post-thrombotic syndrome with ultrasonographic follow-up after deep vein thrombosis: A systematic review and meta-analysis.
        Thromb Haemost. 2018; 118: 1428-1438
        • Jeraj L.
        • Kaja M.
        • Poredos P.
        Insufficient recanalization of thrombotic venous occlusion—Risk for postthrombotic syndrome.
        J Vasc Interv Radiol. 2017; 28: 941-944
        • Latella J.
        • Desmarais S.
        • Miron M.J.
        • et al.
        Relation between D-dimer level, venous valvular reflux and the development of post-thrombotic syndrome after deep vein thrombosis.
        J Thromb Haemost. 2010; 8: 2169-2175
        • Erkens P.M.
        • ten Cate H.
        • Buller H.R.
        • Prins M.H.
        Benchmark for time in therapeutic range in venous thromboembolism: A systematic review and meta-analysis.
        PLoS One. 2012; 7e42269

      Linked Article